Tetsuya Awada
Hiroshima University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tetsuya Awada.
International Journal of Dentistry | 2012
Motoko Yoshioka; Kotaro Tanimoto; Yuki Tanne; Keisuke Sumi; Tetsuya Awada; Nanae Oki; Masaru Sugiyama; Yukio Kato; Kazuo Tanne
Objectives of the Study. Cleft lip and palate (CLP) is a prevalent congenital anomaly in the orofacial region. Autogenous iliac bone grafting has been frequently employed for the closure of bone defects at the jaw cleft site. Since the related surgical procedures are quite invasive for patients, it is of great importance to develop a new less invasive technique. The aim of this study was to examine bone regeneration with mesenchyme stem cells (MSCs) for the treatment of bone defect in artificially created jaw cleft in dogs. Materials and Methods. A bone defect was prepared bilaterally in the upper incisor regions of beagle dogs. MSCs derived from iliac bone marrow were cultured and transplanted with carbonated hydroxyapatite (CAP) particles into the bone defect area. The bone regeneration was evaluated by standardized occlusal X-ray examination and histological observation. Results. Six months after the transplantation, perfect closure of the jaw cleft was achieved on the experimental side. The X-ray and histological examination revealed that the regenerated bone on the experimental side was almost equivalent to the original bone adjoining the jaw cleft. Conclusion. It was suggested that the application of MSCs with CAP particles can become a new treatment modality for bone regeneration for CLP patients.
The Cleft Palate-Craniofacial Journal | 2015
Kotaro Tanimoto; Keisuke Sumi; Motoko Yoshioka; Nanae Oki; Yuki Tanne; Tetsuya Awada; Yukio Kato; Masaru Sugiyama; Kazuo Tanne
Objective The aim of this study was to examine experimental tooth movement into regenerated bone in alveolar cleft with mesenchymal stem cells and a granulated carbonated hydroxyapatite scaffold. Design An artificial bone defect was created bilaterally in upper incisor regions of beagle dogs to simulate alveolar clefts in patients with cleft palate. The mesenchymal stem cells derived from the iliac bone marrow were cultured and transplanted with carbonated hydroxyapatite into the bone defect area. Carbonated hydroxyapatite alone was transplanted on the control side. Six months after the transplantation, multi-bracket appliances were attached to the lateral incisors and canines on both sides of the maxilla to exert an orthodontic force of 100 × g using an elastic chain. The distance between lateral incisor and canine was measured, and standardized x-ray images were taken every month. The tissue after tooth movement was evaluated by histological observation. Results The experimental tooth movement, accompanied by resorption of regenerated bone and new bone formation, was achieved on the experimental and control sides. Although there was no difference in the amount of tooth movement obtained on the experimental and control sides during the 6-month experimental period, the rate of tooth movement varied on the control side; whereas, the rate was consistent on the experimental side. Root resorption of the tooth was observed on the control side in one dog. Conclusion It is suggested that mesenchymal/carbonated hydroxyapatite transplantation therapy has great potential as a new treatment modality for bone regeneration in patients with cleft palate.
Journal of Periodontology | 2016
Yuki Yoshimi; Ryo Kunimatsu; Naoto Hirose; Tetsuya Awada; Mutsumi Miyauchi; Takashi Takata; Wu Li; Li Zhu; Pamela DenBesten; Kazuo Tanne; Kotaro Tanimoto
BACKGROUND Extracts of enamel matrix proteins are used to regenerate periodontal tissue; amelogenin, the most abundant enamel protein, plays an important role in this regeneration. Studies have demonstrated that amelogenin fragments promote tissue regeneration, but the bioactive site of amelogenin remains unclear. This study explores the functional domain of amelogenin by investigating effects of four amelogenin species on cementoblast proliferation. METHODS Four amelogenin species based on amelogenin cleavage products were investigated: 1) recombinant human full-length amelogenin (rh174); 2) amelogenin cleavage product lacking the C-terminal (rh163); 3) amelogenin cleavage product lacking the N-terminal (rh128); and 4) the C-terminal region of rh174 (C11 peptide), which was synthesized and purified. Human cementoblast-like cell line (HCEM) cells were cultured and treated with rh174, rh163, rh128, or C11 peptide. Cell proliferation was evaluated using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium assay and cell proliferation enzyme-linked immunosorbent assay. Mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK) (MAPK-ERK) pathway was examined by Western blot analysis. RESULTS Proliferation of HCEM cells was significantly enhanced on treatment with rh174, rh128, or C11 peptide. However, rh163 had no effect compared with the untreated control group. Western blot analysis revealed enhanced phosphorylated ERK1/2 signaling after addition of rh128 or C11 peptide and reduced phosphorylated ERK1/2 signaling after blocking with a specific MAPK inhibitor (U0126). CONCLUSION C-terminal amelogenin cleavage product increased proliferation of HCEM through MAPK-ERK signaling pathway, indicating possible application of C11 peptide for periodontal tissue regeneration.
Journal of Oral Science | 2018
Keisuke Sumi; Takaharu Abe; Ryo Kunimatsu; Nanae Oki; Yuji Tsuka; Tetsuya Awada; Kengo Nakajima; Kazuyo Ando; Kotaro Tanimoto
Regeneration of tissue, including bone, using mesenchymal stem cells (MSCs) has been progressing rapidly. Regeneration of bone requires the presence of an appropriate environment and efficient chemotaxis of cells to the target site. Differentiation of MSCs into mesenchymal cells has received considerable attention, but the effect of MSCs on chemotaxis is not well understood. In this study, we investigated the effect of MSCs on chemotaxis of RAW264 cells via C-C motif chemokine ligand 2 (CCL2). Balb/c mouse bone marrow-derived MSCs and RAW264 cells, which are osteoclast precursor cells, were co-cultured without cell contact. The gene expression of CCL2 in MSCs and CC-chemokine receptor 2 (CCR2) in RAW264 cells was determined using quantitative real-time PCR. Analysis of RAW264 cell chemotaxis was performed using the Boyden chamber assay. mRNAs for CCL2 and CCR2 were significantly upregulated upon co-culture in comparison to culture of either cell type alone, and the number of chemotactic RAW264 cells was significantly increased by co-culture. MSCs enhanced the chemotaxis of RAW264 cells, possibly via CCL2-CCR2 interaction, suggesting the potential utility of MSCs for tissue regeneration.
Journal of Periodontal Research | 2017
Ryo Kunimatsu; Yuki Yoshimi; Naoto Hirose; Tetsuya Awada; Mutsumi Miyauchi; Takashi Takata; Wu Li; Li Zhu; Pamela DenBesten; Kotaro Tanimoto
BACKGROUND AND OBJECTIVES Amelogenin proteins are the major constituent of developing extracellular enamel matrix and are believed to have an exclusively epithelial origin. Recent studies have suggested that amelogenins might induce the differentiation and maturation of various cells, including cementoblast lineage cells. However, the residues comprising the active site of amelogenin remain unclear. The purpose of this study was to identify the active site region of amelogenin by studying the effects of amelogenin fragments on the osteogenic differentiation of cementoblasts. MATERIAL AND METHODS Amelogenin fragments lacking the C-terminus (rh163) and N-terminus (rh128) and a fragment consisting of the C-terminal region of rh174 (C11 peptide) were synthesized and purified. Human cementoblast lineage cells were cultured in osteogenic differentiation medium and treated with 0, 10, 100 or 1000 ng/mL of rh163, rh128 or C11 peptide. The mRNA levels of bone markers were examined by real-time polymerase chain reaction analysis. Alkaline phosphatase activity and calcium deposition were also determined. Mineralization was evaluated by alizarin red staining. RESULTS The osteogenic differentiation of human cementoblast lineage cells was significantly enhanced by treatment with rh128 or C11 peptide, whereas rh163 had no significant effect as compared with untreated controls. CONCLUSIONS The C-terminus of amelogenin promotes the osteogenic differentiation of human cementoblast lineage cells, indicating the possible utility of C11 peptide in periodontal tissue regeneration.
Lasers in Surgery and Medicine | 2018
Hidemi Gunji; Ryo Kunimatsu; Yuji Tsuka; Yuki Yoshimi; Keisuke Sumi; Tetsuya Awada; Kengo Nakajima; Aya Kimura; Tomoka Hiraki; Naoto Hirose; Makoto Yanoshita; Kotaro Tanimoto
Tooth movement during orthodontic treatment is associated with bone neoplasticity and bone resorption on the tension and pressure sides. Previous clinical studies have suggested that low‐power laser irradiation can accelerate tooth movement during orthodontic treatment, although the underlying mechanism remains unclear. In this study, we used a high‐frequency near‐infrared diode laser that generates less heat and examined the histologic changes in periodontal tissue during experimental tooth movement with laser irradiation.
Current Pharmaceutical Design | 2018
Kazuyo Ando; Ryo Kunimatsu; Tetsuya Awada; Yuki Yoshimi; Yuji Tsuka; Keisuke Sumi; Kayo Horie; Takaharu Abe; Kengo Nakajima; Kotaro Tanimoto
Amelogenins are enamel matrix proteins that play crucial roles in enamel formation. Previous studies have indicated that amelogenin and amelogenin C-terminal peptides have cell-signaling functions. Recently, adipocyte-derived mesenchymal stem cells (ADSCs) have received attention as a potential source of stem cells for use in regeneration therapy. In this study, we examined the effects of human full-length amelogenin (rh174) and amelogenin C-terminal peptide (amgCP) on the proliferation of ADSCs. ADSCs were cultured in the presence of amgCP or rh174. Cell proliferation was analyzed using BrdU immunoassay and MTS assay. Cell migration was evaluated by ELISA. The MAPK-ERK pathway was examined by phospho-p44/42 MAPK (Thr202/Tyr204) sandwich ELISA and western blotting. A specific MAPK inhibitor, U0126, was used to block ERK activity. ADSC proliferation and migration were significantly (P < 0.05) increased in the presence of rh174 or amgCP compared to non-treated control cells. The increased proliferation of ADSCs induced by rh174 or amgCP was significantly (P < 0.05) inhibited in the presence of 2 µg/ml U0126. The pERK/tERK ratio was significantly (P < 0.05) increased upon treatment with rh174 or amgCP compared to non-treated ADSCs, while this increase was significantly (P < 0.05) suppressed by the addition of U0126. Similar results were found by western blot analysis. In conclusion, amgCP and rh174 increase ADSC proliferation via the MAPK-ERK signaling pathway, and ADSCs may be useful for tissue regeneration in the orofacial region.
Biomedical Research-tokyo | 2018
Ryo Kunimatsu; Yuki Yoshimi; Tetsuya Awada; Kotaro Tanimoto
Objective: Amelogenins are known as a major constituent of the enamel matrix secreted by ameloblasts and play an important role in enamel formation. Amelogenin knockout mice exhibit enhanced osteoblast formation and resorption of tooth cementum. Recent studies have revealed that amelogenins also have cell signaling properties. However, the biological functions of amelogenin in osteoblasts remain unclear. In this study, we examined the effects of recombinant human full-length amelogenin (rh174) on the proliferation of cultured normal human osteoblasts (NHOst). Methods: NHOst cells were cultured and treated with 100 ng/ml rh174. Cell proliferation was evaluated using MTS assay in a time-dependent manner. Expression of Lysosomal-associated membrane protein 1 (LAMP 1), a possible amelogenin receptor, in NHOst cells was analyzed. NHOst cells were cultured and treated with 100 ng/ml rh174 in the presence or absence of LAMP 1-blocking antibody. Cell proliferative activity was analyzed by BrdU assay. Phosphorylation of extracellular signal regulated kinases (ERK) 1/2 was measured by ELISA and western blotting analysis. Results: Proliferation of NHOst cells was enhanced significantly (p<0.01) by treatment with rh174, and was inhibited significantly (p<0.01) by addition of anti-LAMP 1-blocking antibody. In addition, the ratio of phosphorylated ERK1/2 to total ERK1/2 was significantly larger (p<0.01) with rh174 treatment, and was reduced significantly by the addition of anti-LAMP 1-blocking antibody in NHOst cells. Conclusion: These results confirmed that rh174 interacts with LAMP 1, and rh174/LAMP 1 interaction activates the ERK1/2 signaling pathway, enhancing the proliferation activity of NHOst cells.
Brain Research | 2017
Kayo Horie; Mineo Watanabe; Chea Chanbora; Tetsuya Awada; Ryo Kunimatsu; Takashi Uchida; Takashi Takata; Kotaro Tanimoto
There is an urgent clinical need for an effective therapeutic agent to treat neuropathic pain. This study explored whether intrathecal administration of bovine lactoferrin (bLF), in combination with signal transduction pathway inhibition or an inflammatory cytokine production, results in reduced allodynia/hyperalgesia in the whisker pad area following mental nerve transection (MNT) in rats. Rats were intrathecally infused with bLF, lipopolysaccharide from Rhodobacter sphaeroides (LPS-RS), an antagonist of Toll-like receptor 4 (TLR4), or interleukin (IL)-18 binding protein (BP). bLF attenuated allodynia/hyperalgesia and blocked upregulation of phosphorylated (p)-p38 mitogen-activated protein kinase (MAPK), p-nuclear factor (NF)-κB p65, p-IκB kinase, and IL-18 in the trigeminal subnucleus caudalis (Vc). Microglia expressed p-p38 and astrocytes expressed p-NF-κB p65 in the Vc following MNT. LPS-RS had the same effects as bLF, except for attenuation of p-NF-κB p65. IL-18BP attenuated allodynia/hyperalgesia and IL-18 upregulation in the Vc. These results suggest that bLF suppresses IL-18 production, which is involved in allodynia/hyperalgesia following MNT, by inhibiting TLR4-derived p38 MAPK activation in microglia. Additionally, binding of bLF to tumor necrosis factor receptor-associated factor 6 might result in inhibition of p38 MAPK and NF-κB activation. The findings suggest that bLF could serve as a potent therapeutic agent for neuropathic pain.
Biochemical and Biophysical Research Communications | 2018
Ryo Kunimatsu; Kengo Nakajima; Tetsuya Awada; Yuji Tsuka; Takaharu Abe; Kazuyo Ando; Tomoka Hiraki; Aya Kimura; Kotaro Tanimoto